Immunotherapy against cancer has shown increased overall survival of metastatic cancer patients and is a promising new vaccine target. For this to succeed, appropriate tailoring of vaccine formulations to mount in vivo cytotoxic T cell (CTL) responses towards co-delivered cancer antigens is important. Previous development of therapeutic cancer vaccines has largely been based on studies in mice and the majority of these candidate vaccines failed to establish therapeutic responses in subsequent human clinical trials. Since the porcine immunome is more closely related to the human counterpart, we here introduce pigs as a superior large animal model for human cancer vaccine development via the use of our unique technology for swine leukocyte antigen (SLA) production. IDO and RhoC, both known to be important in human cancer development and progression, were used as vaccine targets. Pigs were immunized with overlapping 20-mer peptides spanning the entire porcine IDO and RhoC sequences formulated in a panel of CTL-inducing adjuvants. 198 candidate IDO- and RhoC-derived 9-11mer peptides potentially binding to SLA- 1*04:01, -1*07:02, -2*04:01, -2*05:02 and/or -3*04:01 were identified in silico, and peptide-SLA complex stability measurements revealed 89 stable (t½ ≥ 0.5 hour) complexes. Vaccine-induced peptide-specific CTL responses were monitored using IFN-γ release as a read out. We found responses to IDO- and RhoC-derived peptides across all groups; surprisingly non-stably binding peptides also induced responses. None of the adjuvants was found to be superior as they were all capable of generating CTL responses to IDO and RhoC hence supporting the further use of pigs as a large animal model for vaccine development against human cancer.
|Conference||5th European Veterinary Immunology Workshop|
|Period||02/09/2015 → 04/09/2015|